What Is The Current and Historic Market Size Analysis Of The Inhalation CDMO Market?
The inhalation cdmo market has seen considerable growth due to a variety of factors.
• The size of the inhalation CDMO market has significantly increased over the recent years. It is projected to expand from $2.08 billion in 2024 to $2.23 billion in 2025, maintaining a CAGR of 7.0%.
The growth in the prior period is mainly due to factors such as the increasing cases of respiratory diseases, the rising demand for customized medication, a surge in outsourcing by pharmaceutical firms, and the expansion of the biopharmaceutical sector.
What are the Market Size and Expected Growth Rates for the Inhalation CDMO Market?
The inhalation cdmo market is expected to maintain its strong growth trajectory in upcoming years.
• It is anticipated that the inhalation CDMO market will experience significant growth in the upcoming years, expanding to $2.9 billion in 2029 with a compound annual growth rate (CAGR) of 6.8%.
This projected growth during the forecast period can be credited to the emphasis on precision medicine and targeted treatments, the fast-paced growth of biopharmaceutical inhalation therapies, and patient-centered approaches. Other contributing factors include the expansion of the global market and emerging market opportunities, as well as regulatory support for the development of inhalation drugs. Key trends projected for the forecast period include the rising demand for digital health solutions, biologic inhalation therapies, emphasis on environmentally friendly inhaler technologies, the incorporation of artificial intelligence (AI) and machine learning, along with collaboration and partnerships.
Which Key Drivers Are Propelling The Inhalation CDMO Market's Growth?
The growth of the inhalation CDMO market is anticipated to be driven by the rising occurrence of respiratory ailments. These disorders, which impact the respiratory system, represent a collection of medical issues affecting the organs and structures involved in breathing. Given their proficiency in creating and delivering drugs to the lungs, Inhalation CDMOs are utilized in the creation and production of treatments for such conditions. They provide specialized skills, infrastructure, and resources to pharmaceutical organizations aiming to introduce novel inhalation therapies. For example, the Australian Bureau of Statistics (ABS), a government agency in Australia, reported that 34% of Australians (around 8.5 million individuals) had chronic respiratory issues. This includes 11% with asthma (about 2.8 million) and 2.5% with COPD (approximately 638,000 people). Therefore, the increasing occurrence of respiratory disorders is fueling the escalation of the inhalation CDMO market.
What Are The Key Segments Within The Global Inhalation CDMO Market?
The inhalation CDMO market covered in this report is segmented –
1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler
2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
3) By Technology: Manual Inhalers (SMI), Digital Inhalers
4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs
2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs
3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers
4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices
Pre-Book The Inhalation CDMO Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Inhalation CDMO Market?
Leading corporations in the inhalation CDMO sector are adopting a strategic partnership model in order to offer specialized drug development and delivery. This long-term, reciprocal arrangement between two or more businesses is established with the aim of achieving mutual objectives. For example, in May 2023, Hovione, a Portuguese Contract Development and Manufacturing Organization, joined forces with H&T Presspart, a UK-based producer of high-precision metal and plastic parts for the pharmaceutical sector, in order to cultivate Presspart's Sunrise Capsule-based Dry Powder Inhaler platform. The focal point of this partnership is to innovate new technologies that are capable of delivering greater doses of medication and enhancing the efficiency of drug delivery to the lungs.
Who Are the Key Players In The Inhalation CDMO Market?
Major companies operating in the inhalation CDMO market report are:
• Pfizer Inc.
• Merck KGaA
• Baxter’s BioPharma Solutions
• Lonza Group AG
• Catalent Inc.
• AptarGroup Inc.
• Samsung Biologics Co. Ltd.
• Siegfried Holding AG
• Recipharm AB
• Stevanato Group SpA
• Cambrex Corporation
• CordenPharma
• Nemera
• Hovione FarmaCiencia SA
• Vectura Group Ltd.
• CARBOGEN AMCIS
• Kindeva Drug Delivery Ltd.
• Frontage Laboratories Inc
• Formosa Laboratories Inc
• Sanner GmbH
• H&T Presspart Ltd.
• Astech Projects Ltd
• Cliantha Research
• Dipharma Francis Srl
• Copley Scientific
What Are The Regional Insights Into The Inhalation CDMO Market?
North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2024. The regions covered in the inhalation CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
